Correlates of hepatitis C virus infections among injection drug users.
about
Acute hepatitis C: prevention and treatmentHigh HCV seroprevalence and HIV drug use risk behaviors among injection drug users in PakistanRisk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study.Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillanceCellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels.Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.Detection of Diverse Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes in Peripheral Blood of Infected Persons by Screening for Responses to All Translated Proteins of HCVTesting Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence RatesEstimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progressionGenetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, ChinaFactors associated with spontaneous clearance of hepatitis C virus among illicit drug usersMethamphetamine enhances Hepatitis C virus replication in human hepatocytesHepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCVPrevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.SIncidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infectionIsoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosisOutlier populations: individual and social network correlates of solvent-using injection drug usersPrevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of NepalSeroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic reviewHealth-related quality of life of patients with HIV disease: impact of hepatitis C coinfection.The HCV Synthesis Project: scope, methodology, and preliminary results.A trial to reduce hepatitis C seroincidence in drug users.Not all injection drug users are created equal: heterogeneity of HIV, hepatitis C virus, and hepatitis B virus infection in Georgia.Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for preventionInfection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.Chronic pain and hepatitis C virus infection in opioid dependent injection drug usersHealth care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population.Hepatitis C management by addiction medicine physicians: results from a national surveyThe DRD2A₁allele: a behavioural genetic risk factor in hepatitis C infection of persistent drug abusers.Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults.Hepatitis C virus infection in the human immunodeficiency virus infected patient.Hepatitis C virus-specific T-cell immune responses in seronegative injection drug usersPhylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, CanadaRapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection.Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000.Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug usersIs it justifiable to withhold treatment for hepatitis C from illicit-drug users?
P2860
Q22305934-56B64472-64AE-42E9-AFC2-28B3942A3AC1Q24673331-50626CA2-F32A-4830-9574-80AEBC63A49CQ24800271-6C23073F-132D-4281-9760-CCC06D079580Q24803011-E5430431-15AF-4F31-B812-75649F4E9DF1Q26749249-7D10668A-0249-43F2-BD49-43B3F0FEF3B8Q27469342-532F1235-40EA-4436-9167-A815FB455A16Q27469391-CF2773AF-A52A-4997-A3DF-7C02CB090674Q27469551-FCAF739F-2656-455D-B7BE-327EC109AE6AQ27469764-F41546B5-67E1-4B8D-8DE7-1D66929525E9Q27485369-14A381F9-8CD8-4A69-9B4E-972CD73ED2E8Q27485372-4B356803-13A4-4179-B334-C26FAEEA32EDQ27486520-CEA14375-293C-4A06-9F7F-B73BDD86570DQ27488233-AA410E48-4077-4FAC-97AB-22601FDD407AQ27488356-F0326FEF-7F19-4192-8C9C-2CC77ADCCDFBQ27488816-34641C61-A7E3-4DE8-B6EE-69650044D83BQ27489610-51E828E1-4659-437C-913A-3040B568FB79Q28361460-7A1CA2DE-6978-448C-BFB9-54CF574B6D14Q28362291-66B34096-24F9-437D-A7CF-9699D8AE17B4Q28539716-53D4D8B3-48CF-457F-8D47-468185C9C70DQ28547151-D41F7AA5-ED91-4A9C-8A43-DA5119F7132DQ30241549-76222D3B-DBAA-4DE9-9F6B-7BB5EC4F6623Q31041310-C82A7392-A4C3-4F3D-9833-1702A8B7E49FQ33369233-0355139E-415C-443A-B259-8497E0F5F4D2Q33658861-EBA0C5F3-1540-417C-A766-BB330B465CBCQ33673340-64C463D0-EAE6-4B33-97DF-10C93649EEAFQ33707925-F4E1359B-BF70-4B8A-BBD9-0C5E67FDC6FDQ33825988-208D4E26-F542-446E-9EE7-3027B206DB29Q33872397-F353CDFE-DD4D-4625-9477-987F3869958FQ34022681-8E6FEAF7-4A02-49A6-9256-4A41BC9F309DQ34090853-63F51A60-6DE4-4AD6-AC9C-F73C7D8E775DQ34122517-2AD89E49-E132-4E03-B6CD-EC6A2231D62AQ34137925-E3489ED3-EF20-4E6A-8AD8-62B0C630B9A3Q34168504-FB8DE5F0-32EB-4F6F-B861-8D0FC28C69B4Q34381567-AAFAFC72-940C-42AA-BB7A-2D5F82D9FDA3Q34415820-8CEDAC74-4479-47BE-8764-61F3A10539EAQ34522213-0F701FAB-B334-4B21-B5DD-707F59919BAEQ34614976-73A72B5B-42BF-421C-8C1E-6B2885ABCC97Q34795051-910421EB-997B-49E6-BAA8-D63D2B3C79CDQ34795057-C8CEF628-75DD-4992-977F-67C8CBFF6F9EQ34795087-FE6602CC-E6B5-4229-833F-8A5A09FA1422
P2860
Correlates of hepatitis C virus infections among injection drug users.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Correlates of hepatitis C virus infections among injection drug users.
@en
type
label
Correlates of hepatitis C virus infections among injection drug users.
@en
prefLabel
Correlates of hepatitis C virus infections among injection drug users.
@en
P2093
P1433
P1476
Correlates of hepatitis C virus infections among injection drug users.
@en
P2093
P304
P356
10.1097/00005792-199507000-00005
P407
P577
1995-07-01T00:00:00Z